{
  "nctId": "NCT04407234",
  "briefTitle": "A Study to Measure Stomach Emptying in Overweight Non-diabetic and Diabetic Participants Using Tirzepatide",
  "officialTitle": "The Impact of Tirzepatide on Gastric Emptying (GE) in Overweight/Obese Non-diabetic Subjects and in Overweight/Obese Subjects With Type 2 Diabetes Mellitus",
  "protocolDocument": {
    "nctId": "NCT04407234",
    "filename": "Prot_000.pdf",
    "label": "Study Protocol",
    "date": "2020-07-23",
    "uploadDate": "2022-06-07T16:55",
    "size": 2708800,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT04407234/document/Prot_000.pdf",
    "hasProtocol": true,
    "hasSap": false,
    "hasIcf": false
  },
  "phase": [
    "PHASE1"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "NA",
  "interventionModel": "SINGLE_GROUP",
  "masking": "NONE",
  "enrollmentInfo": {
    "enrollmentCount": 36,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2020-09-15",
    "completionDate": "2021-01-07",
    "primaryCompletionDate": "2021-01-07",
    "firstSubmitDate": "2020-05-27",
    "firstPostDate": "2020-05-29"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\n* Have a body mass index (BMI) between 27 to 45 kilograms per meter squared (kg/mÂ²), inclusive at screening\n* For nondiabetic subjects: as determined by medical history, physical examination, and safety assessments at screening\n* For participants with a confirmed type 2 diabetes diagnosis: The condition must be managed either by diet and exercise alone or on a stable dose of metformin for the past 3 months\n* Willing and agreeable to commit to the duration of the study and undergo study procedures as instructed by the clinic staff\n\nKey Exclusion Criteria\n\n* Have undergone gastric bypass or bariatric surgery\n* Have received prescription drugs or over the counter drugs that promote weight loss in the past 6 months prior to screening\n* For participants with a confirmed type 2 diabetes diagnosis: Have experienced more than 1 episode of severe low blood sugar that require emergency treatment, hospitalization or third parties to administer rescue treatment, in the past 6 months\n* Have any lifetime history of a suicide attempt\n* Have other medical conditions or medical history that make participation in the study unsafe or which may interfere in the interpretation of the results of the study\n* Unwilling to comply with smoking and alcohol restrictions during the study",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "18 Years",
    "maximumAge": "65 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Pharmacokinetics (PK): Area Under the Concentration Time Curve From Time Zero to Time T, Where T is the Last Time Point With a Measurable Concentration [ AUC(0-tlast)] of Acetaminophen",
        "description": "Area Under the Concentration Time Curve From Time Zero to Time T, Where T is the Last Time Point With a Measurable Concentration \\[ AUC(0-tlast)\\] of Acetaminophen",
        "timeFrame": "Pre-dose, 0.5, 0.75, 1, 2, 3, 4, 6, 9, 12, 24 and 36 hours post-dose on Day 1, Day 2 and Day 37 , Day 2 and Day 37"
      },
      {
        "measure": "PK: Maximum Observed Drug Concentration (Cmax) of Acetaminophen",
        "description": "Maximum Observed Drug Concentration (cmax) of Acetaminophen",
        "timeFrame": "Pre-dose, 0.5, 0.75, 1, 2, 3, 4, 6, 9, 12, 24 and 36 hours post-dose on Day 1, Day 2 and Day 37 , Day 2 and Day 37"
      }
    ],
    "secondary": [
      {
        "measure": "Hemoglobin A1c (HbA1c) Data by Diabetic Status",
        "description": "Levels of Hemoglobin A1c (HbA1c) were assessed at predose on Day 29, and at follow-up (Day 64).",
        "timeFrame": "Predose on Day 29 and follow-up (Day 64)"
      },
      {
        "measure": "PK: Area Under the Concentration Time Curve From Time Zero to Time T, Where T is the Last Time Point With a Measurable Concentration [ AUC(0-tlast)] of Acetaminophen at Steady State For Non-diabetic",
        "description": "Area Under the Concentration Time Curve From Time Zero to Time T, Where T is the Last Time Point With a Measurable Concentration \\[ AUC(0-tlast)\\] of Acetaminophen at Steady State For Non-diabetic",
        "timeFrame": "Pre-dose, 0.5, 0.75, 1, 2, 3, 4, 6, 9, 12, 24 and 36 hours post-dose on Day 1, Day 2 and Day 37 , Day 2 and Day 37"
      },
      {
        "measure": "PK: Area Under the Concentration Versus Time Curve From Time Zero to Time T, Where T is the Last Time Point With a Measurable Concentration [ AUC(0-tlast)] of Acetaminophen at Steady State For T2DM",
        "description": "Area Under the Concentration Versus Time Curve From Time Zero to Time T, Where T is the Last Time Point With a Measurable Concentration \\[ AUC(0-tlast)\\] of Acetaminophen at Steady State For T2DM",
        "timeFrame": "Pre-dose, 0.5, 0.75, 1, 2, 3, 4, 6, 9, 12, 24 and 36 hours post-dose on Day 1, Day 2 and Day 37 , Day 2 and Day 37"
      },
      {
        "measure": "PK: Cmax of Acetaminophen at Steady State Non-diabetic",
        "description": "PK: Cmax of Acetaminophen at Steady State Non-diabetic",
        "timeFrame": "Pre-dose, 0.5, 0.75, 1, 2, 3, 4, 6, 9, 12, 24 and 36 hours post-dose on Day 1, Day 2 and Day 37 , Day 2 and Day 37"
      },
      {
        "measure": "PK: Cmax of Acetaminophen at Steady State For T2DM",
        "description": "PK: Cmax of Acetaminophen at Steady State T2DM",
        "timeFrame": "Pre-dose, 0.5, 0.75, 1, 2, 3, 4, 6, 9, 12, 24 and 36 hours post-dose on Day 1, Day 2 and Day 37 , Day 2 and Day 37"
      }
    ],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 2,
      "secondaryCount": 5,
      "otherCount": 0,
      "totalCount": 7
    },
    "studyDesign": {
      "phases": [
        "PHASE1"
      ],
      "isRandomized": false,
      "isMasked": false,
      "interventionModel": "SINGLE_GROUP"
    },
    "overallComplexityScore": 49,
    "complexityCategory": "Moderate"
  },
  "collectionDate": "2025-09-22T02:30:14.863Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}